Amino Acids

, Volume 46, Issue 1, pp 73–80 | Cite as

Taurine and atherosclerosis

  • Shigeru MurakamiEmail author
Review Article


Taurine is abundantly present in most mammalian tissues and plays a role in many important physiological functions. Atherosclerosis is the underlying mechanism of cardiovascular disease including myocardial infarctions, strokes and peripheral artery disease and remains a major cause of morbidity and mortality worldwide. Studies conducted in laboratory animal models using both genetic and dietary models of hyperlipidemia have demonstrated that taurine supplementation retards the initiation and progression of atherosclerosis. Epidemiological studies have also suggested that taurine exerts preventive effects on cardiovascular diseases. The present review focuses on the effects of taurine on the pathogenesis of atherosclerosis. In addition, the potential mechanisms by which taurine suppress the development of atherosclerosis will be discussed.


Taurine Atherosclerosis Cardiovascular disease Artery 



Cytochrome P450


High density lipoprotein


Human hepatocellular liver carcinoma cell line


3-Hydroxy-3-methylglutaryl coenzyme A


Human umbilical vein endothelial cells


Intercellular adhesion molecule-1


Inhibitor of nuclear factorκ-B


Low density lipoprotein


Lectin-like oxidized low density lipoprotein receptor-1


Nuclear factor-κB


Nitric oxide


Platelet-derived growth factor


Reactive oxygen species


Smooth muscle cell


Taurine chloramine


Tumor necrosis factor-α


Very low density lipoprotein


Conflict of interest

The authors declare that there are no conflicts of interest associated with this study.


  1. Abebe W, Mozaffari MS (2000) Effects of chronic taurine treatment on reactivity of the rat aorta. Amino Acids 19:615–623PubMedCrossRefGoogle Scholar
  2. Abebe W, Mozaffari MS (2003) Taurine depletion alters vascular reactivity in rats. Can J Physiol Pharmacol 81:903–909PubMedCrossRefGoogle Scholar
  3. Abebe W, Mozaffari MS (2011) Role of taurine in the vasculature: an overview of experimental and human studies. Am J Cardiovasc Dis 1:293–311PubMedCentralPubMedGoogle Scholar
  4. Alfieri RR, Cavazzoni A, Petronini PG, Bonelli MA, Caccamo AE, Borghetti AF, Wheeler KP (2002) Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis. J Physiol 540(Pt 2):499–508PubMedCrossRefGoogle Scholar
  5. Atahanov SE, Elizarova EP (1992) Modulation of receptor-dependent increase of calcium ions in human platelets by taurine. Arzneimittelforschung 42:1311–1313PubMedGoogle Scholar
  6. Balkan J, Kanbağli O, Hatipoğlu A, Kücük M, Cevikbaş U, Aykaç-Toker G, Uysal M (2002) Improving effect of dietary taurine supplementation on the oxidative stress and lipid levels in the plasma, liver and aorta of rabbits fed on a high-cholesterol diet. Biosci Biotechnol Biochem 66:1755–1758PubMedCrossRefGoogle Scholar
  7. Casey RG, Gang C, Joyce M, Bouchier-Hayes DJ (2007) Taurine attenuates acute hyperglycaemia-induced endothelial cell apoptosis, leucocyte-endothelial cell interactions and cardiac dysfunction. J Vasc Res 44:31–39PubMedCrossRefGoogle Scholar
  8. Chen X, Sebastian BM, Tang H, McMullen MM, Axhemi A, Jacobsen DW, Nagy LE (2009) Taurine supplementation prevents ethanol-induced decrease in serum adiponectin and reduces hepatic steatosis in rats. Hepatology 49:1554–1562PubMedCentralPubMedCrossRefGoogle Scholar
  9. Chen W, Guo JX, Chang P (2012) The effect of taurine on cholesterol metabolism. Mol Nutr Food Res 56:681–690PubMedCrossRefGoogle Scholar
  10. Chiba Y, Ando K, Fujita T (2002) The protective effects of taurine against renal damage by salt loading in Dahl salt-sensitive rats. J Hypertens 20:2269–2274PubMedCrossRefGoogle Scholar
  11. De Luca G, Calpona PR, Caponetti A, Romano G, Di Benedetto A, Cucinotta D, Di Giorgio RM (2001) Taurine and osmoregulation: platelet taurine content, uptake, and release in type 2 diabetic patients. Metabolism 50:60–64PubMedCrossRefGoogle Scholar
  12. Egan BM, Chen G, Kelly CJ, Bouchier-Hayes DJ (2001) Taurine attenuates LPS-induced rolling and adhesion in rat microcirculation. J Surg Res 95:85–91PubMedCrossRefGoogle Scholar
  13. Fennessy FM, Moneley DS, Wang JH, Kelly CJ, Bouchier-Hayes DJ (2003) Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation 107:410–415PubMedCrossRefGoogle Scholar
  14. Franconi F, Bennardini F, Mattana A, Miceli M, Ciuti M, Mian M, Gironi A, Anichini R, Seghieri G (1995) Plasma and platelet taurine are reduced in subjects with insulin-dependent diabetes mellitus: effects of taurine supplementation. Am J Clin Nutr 61:1115–1119PubMedGoogle Scholar
  15. Fukuda N, Yoshitama A, Sugita S, Fujita M, Murakami S (2011) Dietary taurine reduces hepatic secretion of cholesteryl ester and enhances fatty acid oxidation in rats fed a high-cholesterol diet. J Nutr Sci Vitaminol 57:144–149PubMedCrossRefGoogle Scholar
  16. Gokce G, Ozsarlak-Sozer G, Oran I, Oktay G, Ozkal S, Kerry Z (2011) Taurine suppresses oxidative stress-potentiated expression of lectin-like oxidized low-density lipoprotein receptor and restenosis in balloon-injured rabbit iliac artery. Clin Exp Pharmacol Physiol 38:811–818PubMedCrossRefGoogle Scholar
  17. Guz G, Oz E, Lortlar N, Ulusu NN, Nurlu N, Demirogullari B, Omeroglu S, Sert S, Karasu C (2007) The effect of taurine on renal ischemia/reperfusion injury. Amino Acids 32:405–411PubMedCrossRefGoogle Scholar
  18. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12:204–212PubMedCrossRefGoogle Scholar
  19. Hayes KC, Pronczuk A, Addesa AE, Stephan ZF (1989) Taurine modulates platelet aggregation in cats and humans. Am J Clin Nutr 49:1211–1216PubMedGoogle Scholar
  20. Huxtable RJ (1992) Physiological actions of taurine. Physiol Rev 72:101–163PubMedGoogle Scholar
  21. Ito T, Schaffer SW, Azuma J (2012) The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 42:1529–1539PubMedCentralPubMedCrossRefGoogle Scholar
  22. Kamata K, Sugiura M, Kojima S, Kasuya Y (1996) Restoration of endothelium-dependent relaxation in both hypercholesterolemia and diabetes by chronic taurine. Eur J Pharmacol 303:47–53PubMedCrossRefGoogle Scholar
  23. Kanayama A, Inoue J, Sugita-Konishi Y, Shimizu M, Miyamoto Y (2002) Oxidation of Ikappa Bα at methionine 45 is one cause of taurine chloramine-induced inhibition of NF-kappa B activation. J Biol Chem 277:24049–24056PubMedCrossRefGoogle Scholar
  24. Kempf E, Ebel A, Wendling S, Bollack C, Mandel P (1970) The distribution of free amino acids in arterial walls and their modifications during aging. Rev Eur Etud Clin Biol 15:857–861PubMedGoogle Scholar
  25. Kibayashi E, Yokogoshi H, Mizue H, Miura K, Yoshita K, Nakagawa H, Naruse Y, Sokejima S, Kagamimori S (2000) Daily dietary taurine intake in Japan. Adv Exp Med Biol 483:137–142PubMedCrossRefGoogle Scholar
  26. Kondo Y, Toda Y, Kitajima H, Oda H, Nagate T, Kameo K, Murakami S (2001) Taurine inhibits development of atherosclerotic lesions in apolipoprotein E-deficient mice. Clin Exp Pharmacol Physiol 28:809–815PubMedCrossRefGoogle Scholar
  27. Learn DB, Fried VA, Thomas EL (1990) Taurine and hypotaurine content of human leukocytes. J Leukoc Biol 48:174–182PubMedGoogle Scholar
  28. Liao XB, Zhou XM, Li JM, Tan ZP, Liu LM, Zhang W, Tan H, Lu Y, Yuan LQ (2007) Taurine transporter is expressed in vascular smooth muscle cells. Amino Acids 33:639–643PubMedCrossRefGoogle Scholar
  29. Libby P (2002) Inflammation in atherosclerosis. Nature 420:868–874PubMedCrossRefGoogle Scholar
  30. Liu Y, Niu L, Zhang W, Cui L, Zhang X, Liang Y, Zhang M (2009) Effects of taurine on contractions of the porcine coronary artery. Pharmacol Rep 61:681–689PubMedGoogle Scholar
  31. Lobo MV, Alonso FJ, Martin del Rio R (2000) Immunocytochemical localization of taurine in different muscle cell types of the dog and rat. Histochem J 32:53–61PubMedCrossRefGoogle Scholar
  32. Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 25:29–38PubMedCrossRefGoogle Scholar
  33. Malle E, Waeg G, Schreiber R, Gröne EF, Sattler W, Gröne HJ (2000) Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 267:4495–4503PubMedCrossRefGoogle Scholar
  34. Malle E, Wäg G, Thiery J, Sattler W, Gröne HJ (2001) Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 289:894–900PubMedCrossRefGoogle Scholar
  35. Manolopoulos VG, Voets T, Declercq PE, Droogmans G, Nilius B (1997) Swelling-activated efflux of taurine and other organic osmolytes in endothelial cells. Am J Physiol 273(1 Pt 1):C214–C222PubMedGoogle Scholar
  36. Marcinkiewicz J, Grabowska A, Bereta J, Bryniarski K, Nowak B (1998a) Taurine chloramine down-regulates the generation of murine neutrophil inflammatory mediators. Immunopharmacology 40:27–38PubMedCrossRefGoogle Scholar
  37. Marcinkiewicz J, Grabowska A, Chain BM (1998b) Modulation of antigen-specific T-cell activation in vitro by taurine chloramine. Immunology 94:325–330PubMedCrossRefGoogle Scholar
  38. Marsche G, Zimmermann R, Horiuchi S, Tandon NN, Sattler W, Malle E (2003) Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein. J Biol Chem 278:47562–47570PubMedCrossRefGoogle Scholar
  39. Matsushima Y, Sekine T, Kondo Y, Sakurai T, Kameo K, Tachibana M, Murakami S (2003) Effects of taurine on serum cholesterol levels and development of atherosclerosis in spontaneously hyperlipidaemic mice. Clin Exp Pharmacol Physiol 30:295–299PubMedCrossRefGoogle Scholar
  40. Murakami S, Yamagishi I, Asami Y, Ohta Y, Toda Y, Nara Y, Yamori Y (1996) Hypolipidemic effect of taurine in stroke-prone spontaneously hypertensive rats. Pharmacology 52:303–313PubMedCrossRefGoogle Scholar
  41. Murakami S, Kondo-Ohta Y, Tomisawa K (1999) Improvement in cholesterol metabolism in mice given chronic treatment of taurine and fed a high-fat diet. Life Sci 64:83–91PubMedCrossRefGoogle Scholar
  42. Murakami S, Kondo Y, Sakurai T, Kitajima H, Nagate T (2002a) Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis 163:79–87PubMedCrossRefGoogle Scholar
  43. Murakami S, Kondo Y, Toda Y, Kitajima H, Kameo K, Sakono M, Fukuda N (2002b) Effect of taurine on cholesterol metabolism in hamsters: up-regulation of low density lipoprotein (LDL) receptor by taurine. Life Sci 70:2355–2366PubMedCrossRefGoogle Scholar
  44. Murakami S, Sakurai T, Tomoike H, Sakono M, Nasu T, Fukuda N (2010a) Prevention of hypercholesterolemia and atherosclerosis in the hyperlipidemia- and atherosclerosis-prone Japanese (LAP) quail by taurine supplementation. Amino Acids 38:271–278PubMedCrossRefGoogle Scholar
  45. Murakami S, Sakurai T, Toda Y, Morito A, Sakono M, Fukuda N (2010b) Prevention of neointima formation by taurine ingestion after carotid balloon injury. Vascul Pharmacol 53:177–184PubMedCrossRefGoogle Scholar
  46. Murphy JE, Tedbury PR, Homer-Vanniasinkam S, Walker JH, Ponnambalam S (2005) Biochemistry and cell biology of mammalian scavenger receptors. Atherosclerosis 182:1–15PubMedCrossRefGoogle Scholar
  47. Nishida S, Satoh H (2009) Vascular modulation of rat aorta by taurine. Adv Exp Med Biol 643:37–46PubMedCrossRefGoogle Scholar
  48. Ogura S, Kakino A, Sato Y, Fujita Y, Iwamoto S, Otsui K, Yoshimoto R, Sawamura T (2009) Lox-1: the multifunctional receptor underlying cardiovascular dysfunction. Circ J 73:1993–1999PubMedCrossRefGoogle Scholar
  49. Park E, Schuller-Levis G, Quinn MR (1995) Taurine chloramine inhibits production of nitric oxide and TNF-alpha in activated RAW 264.7 cells by mechanisms that involve transcriptional and translational events. J Immunol 154:4778–4784PubMedGoogle Scholar
  50. Petty MA, Kintz J, DiFrancesco GF (1990) The effects of taurine on atherosclerosis development in cholesterol-fed rabbits. Eur J Pharmacol 180:119–127PubMedCrossRefGoogle Scholar
  51. Podrez EA, Abu-Soud HM, Hazen SL (2000) Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med 28:1717–1725PubMedCrossRefGoogle Scholar
  52. Qian X, Vinnakota S, Edwards C, Sarkar HK (2000) Molecular characterization of taurine transport in bovine aortic endothelial cells. Biochim Biophys Acta 1509:324–334PubMedCrossRefGoogle Scholar
  53. Rosenson RS (2003) Modulating atherosclerosis through inhibition or blockade of angiotensin. Clin Cardiol 26:305–311PubMedCrossRefGoogle Scholar
  54. Ross R (1999) Atherosclerosis—an inflammatory disease. N Engl J Med 340:115–126PubMedCrossRefGoogle Scholar
  55. Schaffer SW, Lombardini JB, Azuma J (2000) Interaction between the actions of taurine and angiotensin II. Amino Acids 18:305–318PubMedCrossRefGoogle Scholar
  56. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM (2007) Renin-angiotensin system and cardiovascular risk. Lancet 369:1208–1219PubMedCrossRefGoogle Scholar
  57. Schuller-Levis GB, Park E (2004) Taurine and its chloramine: modulators of immunity. Neurochem Res 29:117–126PubMedCrossRefGoogle Scholar
  58. Silva LA, Silveira PC, Ronsani MM, Souza PS, Scheffer D, Vieira LC, Benetti M, De Souza CT, Pinho RA (2011) Taurine supplementation decreases oxidative stress in skeletal muscle after eccentric exercise. Cell Biochem Funct 29:43–49PubMedCrossRefGoogle Scholar
  59. Spohr C, Brøns C, Winther K, Dyerberg J, Vaag A (2005) No effect of taurine on platelet aggregation in men with a predisposition to type 2 diabetes mellitus. Platelets 16:301–305PubMedCrossRefGoogle Scholar
  60. Takahashi K, Azuma M, Taira K, Baba A, Yamamoto I, Schaffer SW, Azuma J (1997) Effect of taurine on angiotensin II-induced hypertrophy of neonatal rat cardiac cells. J Cardiovasc Pharmacol 30:725–730PubMedCrossRefGoogle Scholar
  61. Tan B, Jiang DJ, Huang H, Jia SJ, Jiang JL, Hu CP, Li YJ (2007) Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway. Vascul Pharmacol 46:338–345PubMedCrossRefGoogle Scholar
  62. Terauchi A, Nakazawa A, Johkura Y, Yan L, Usuda N (1998) Immunohistochemical localization of taurine in various tissues of the mouse. Amino Acids 15:151–160PubMedCrossRefGoogle Scholar
  63. Ulrich-Merzenich G, Zeitler H, Vetter H, Bhonde RR (2007) Protective effects of taurine on endothelial cells impaired by high glucose and oxidized low density lipoproteins. Eur J Nutr 46:431–438PubMedCrossRefGoogle Scholar
  64. Vaughan CJ, Gotto AM Jr, Basson CT (2000) The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 35:1–10PubMedCrossRefGoogle Scholar
  65. Wang JH, Redmond HP, Watson RW, Condron C, Bouchier-Hayes D (1996) The beneficial effect of taurine on the prevention of human endothelial cell death. Shock 6:331–338PubMedCrossRefGoogle Scholar
  66. Wang LJ, Yu YH, Zhang LG, Wang Y, Niu N, Li Q, Guo LM (2008) Taurine rescues vascular endothelial dysfunction in streptozocin-induced diabetic rats: correlated with downregulation of LOX-1 and ICAM-1 expression on aortas. Eur J Pharmacol 597:75–80PubMedCrossRefGoogle Scholar
  67. Waters E, Wang JH, Redmond HP, Wu QD, Kay E, Bouchier-Hayes D (2001) Role of taurine in preventing acetaminophen-induced hepatic injury in the rat. Am J Physiol Gastrointest Liver Physiol 280:G1274–G1279PubMedGoogle Scholar
  68. Weiss SJ, Klein R, Slivka A, Wei M (1982) Chlorination of taurine by human neutrophils. Evidence for hypochlorous acid generation. J Clin Invest 70:598–607PubMedCentralPubMedCrossRefGoogle Scholar
  69. Welles EG, Boudreaux MK, Tyler JW (1993) Platelet, antithrombin, and fibrinolytic activities in taurine-deficient and taurine-replete cats. Am J Vet Res 54:1235–1243PubMedGoogle Scholar
  70. Wójcik OP, Koenig KL, Zeleniuch-Jacquotte A, Costa M, Chen Y (2010) The potential protective effects of taurine on coronary heart disease. Atherosclerosis 208:19–25PubMedCentralPubMedCrossRefGoogle Scholar
  71. Wu QD, Wang JH, Fennessy F, Redmond HP, Bouchier-Hayes D (1999) Taurine prevents high-glucose-induced human vascular endothelial cell apoptosis. Am J Physiol 277(6 Pt 1):C1229–C1238PubMedGoogle Scholar
  72. Yamamoto K, Yoshitama A, Sakono M, Nasu T, Murakami S, Fukuda N (2000) Dietary taurine decreases hepatic secretion of cholesterol ester in rats fed a high-cholesterol diet. Pharmacology 60:27–33PubMedCrossRefGoogle Scholar
  73. Yamori Y, Liu L, Ikeda K, Miura A, Mizushima S, Miki T, Nara Y, WHO-Cardiovascular Disease and Alimentary Comprarison (CARDIAC) Study Group (2001) Distribution of twenty-four hour urinary taurine excretion and association with ischemic heart disease mortality in 24 populations of 16 countries: results from the WHO-CARDIAC study. Hypertens Res 24:453–457PubMedCrossRefGoogle Scholar
  74. Yamori Y, Liu L, Mori M, Sagara M, Murakami S, Nara Y, Mizushima S (2009) Taurine as the nutritional factor for the longevity of the Japanese revealed by a world-wide epidemiological survey. Adv Exp Med Biol 643:13–25PubMedCrossRefGoogle Scholar
  75. Yamori Y, Taguchi T, Hamada A, Kunimasa K, Mori H, Mori M (2010) Taurine in health and diseases: consistent evidence from experimental and epidemiological studies. J Biomed Sci 17(Suppl 1):S6PubMedCrossRefGoogle Scholar
  76. Yanagita T, Han SY, Hu Y, Nagao K, Kitajima H, Murakami S (2008) Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 7:38PubMedCentralPubMedCrossRefGoogle Scholar
  77. Yokogoshi H, Mochizuki H, Nanami K, Hida Y, Miyachi F, Oda H (1999) Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr 129:1705–1712PubMedGoogle Scholar
  78. Yoshimura H, Nariai Y, Terashima M, Mitani T, Tanigawa Y (2005) Taurine suppresses platelet-derived growth factor (PDGF) BB-induced PDGF-β receptor phosphorylation by protein tyrosine phosphatase-mediated dephosphorylation in vascular smooth muscle cells. Biochim Biophys Acta 1745:350–360PubMedCrossRefGoogle Scholar
  79. Zhang X, Tenner TE Jr, Lombardini JB (1999) Inhibition of rat vascular smooth muscle cell proliferation by taurine and taurine analogues. Biochem Pharmacol 57:1331–1339PubMedCrossRefGoogle Scholar
  80. Zulli A (2011) Taurine in cardiovascular disease. Curr Opin Clin Nutr Metab Care 14:57–60PubMedCrossRefGoogle Scholar
  81. Zulli A, Lau E, Wijaya BP, Jin X, Sutarga K, Schwartz GD, Learmont J, Wookey PJ, Zinellu A, Carru C, Hare DL (2009) High dietary taurine reduces apoptosis and atherosclerosis in the left main coronary artery: association with reduced CCAAT/enhancer binding protein homologous protein and total plasma homocysteine but not lipidemia. Hypertension 53:1017–1022PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2012

Authors and Affiliations

  1. 1.R&D Headquarters, Self Medication BusinessTaisho Pharmaceutical Co LtdTokyoJapan

Personalised recommendations